Clinical trials: Kidney Cancer, active
Advanced Cancer, Advanced Malignancies
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
- Conditions
- Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer
- Trial name
- ARC-25 (NCT05891171)
- Testing
- AB598, Zimberelimab, Fluorouracil
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 40 people
- Sponsor
- Arcus Biosciences, Inc.
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors.
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03228667
- Testing
- N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab
- Where
- 35 sites in United States
- Volunteers
- 40 people
- Sponsor
- ImmunityBio, Inc.
Renal Neoplasms, Pathology
Optimising Renal Tumour Management Through Artificial Intelligence Modules
The goal of this observational study is to improve the management of people with renal tumour by multimodal artificial intelligence(AI). It will also measure the accuracy of the predictions from AI models.
- Conditions
- Renal Neoplasms, Pathology, Renal Cell Cancer
- Trial name
- NCT06714916
- Where
- China
- Volunteers
- 2,100 people
- Sponsor
- Shao Pengfei
Renal Clear Cell Carcinoma, HIF-2α
Predicting HIF-2α Levels in Clear Cell Kidney Cancer Using Machine Learning
This project aims to conduct a multicenter retrospective study to collect clinical, CT imaging, and pathological data from patients.
- Conditions
- Renal Clear Cell Carcinoma, HIF-2α, Radiomics, Nomogram
- Trial name
- NCT07332923
- Where
- China
- Volunteers
- 500 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Unresectable or Metastatic Clear Cell Renal Cell Carcinoma
The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma
CLEAR CAR-T cell injection (ET-970) is an engineered CD70-targeting allogeneic Chimeric Antigen Receptor T-Cell (CAR-T cell). This is a multi-center, single-arm, open-label, early exploratory clinical study.
- Trial name
- NCT07645690
- Testing
- CLEAR CAR-T cell injection
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
This phase II trial studies the side effects of atezolizumab with or without eribulin mesylate and how well they work in treating patients with urothelial cancer that has come back (recurrent), spread to nearby tissues or lymph…
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma
- Trial name
- NCT03237780
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 21 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer (Primary and Metastatic), Renal Cancer
Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology
This is a pilot study to evaluate the feasibility, image quality, and procedural utility of a novel spectral CT technique using Canon Medical's 4D CT system during image-guided interventional oncology procedures
- Trial name
- NCT07303725
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Palo Alto Veterans Institute for Research
Kidney Cancer, Stage III Renal Cell Cancer AJCC v8
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
This phase II trial studies how well lenvatinib and pembrolizumab before surgery work in treating patients with kidney cancer that has spread from its original site of growth to nearby tissues or lymph nodes but has not spread to…
- Conditions
- Kidney Cancer, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT04393350
- Testing
- Lenvatinib, Lenvatinib Mesylate, Pembrolizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Emory University
Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic
A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
This trial aims to address unmet medical needs in advanced solid tumors, specifically metastatic clear cell renal carcinoma, locally advanced or metastatic pancreatic adenocarcinoma, and metastatic colorectal adenocarcinoma.
- Conditions
- Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Metastatic Colorectal Carcinoma (mCRC)
- Trial name
- NCT07566897
- Testing
- L19IL2, Ruxolitinib
- Where
- Italy
- Volunteers
- 96 people
- Sponsor
- Philogen S.p.A.
Carcinoma, Renal Cell
Autologous Dendritic Cell Vaccine in Kidney Cancer
The purpose of this study is to estimate the probability of immune response for the combination treatment of dendritic cell vaccine with oral cabozantinib and characterize the safety profile of interventional therapy.
- Trial name
- NCT05127824
- Testing
- Autologous alpha-DC1/TBVA vaccine, Cabozantinib
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Jodi Maranchie
Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or…
- Trial name
- NILE (NCT03682068)
- Testing
- Durvalumab, Tremelimumab, Cisplatin + Gemcitabine
- Where
- 222 sites in United States, Argentina and 20 more
- Volunteers
- 1,246 people
- Sponsor
- AstraZeneca
Wilms Tumor
Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation
Participants are being asked to take part in this clinical trial, a type of research study, because the participants have a Wilms Tumor cancer.
- Trial name
- NCT04968990
- Testing
- Proton Beam Radiation (PBRT), DD-4A Chemotherapy Regimen, Complete Surgical Resection
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- St. Jude Children's Research Hospital
Kidney Cancer, Renal Cell Carcinoma Metastatic
Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial
BACKGROUND: For synchronous metastatic renal cell carcinoma (RCC), surgical resection of the primary tumor in the presence of distant metastases has been the standard of therapy for select patients followed by systemic therapy.
- Conditions
- Kidney Cancer, Renal Cell Carcinoma Metastatic, Synchronous Neoplasm
- Trial name
- NORDIC-SUN (NCT03977571)
- Testing
- Cytoreductive nephrectomy, Tissue sampling
- Where
- 11 sites in Denmark, Finland and 2 more
- Volunteers
- 400 people
- Sponsor
- Niels Fristrup
Renal Cell Carcinoma
Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma
This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall…
- Trial name
- SPARE (NCT06376669)
- Testing
- Proton Stereotactic Body Radiation therapy (SBRT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread from where it first started…
- Trial name
- NCT05411081
- Testing
- Atezolizumab, Biospecimen Collection, Bone Scan
- Where
- 198 sites in United States
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma, Clear-cell Renal Cell Carcinoma
Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer
This is a correlative (lab-based) study aiming to identify protein markers in urine extracellular vesicles (EVs) that can be used to develop non-invasive molecular tests for patients with renal cell carcinoma (RCC).
- Conditions
- Renal Cell Carcinoma, Clear-cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma
- Trial name
- NCT07243067
- Testing
- Proteomic profiling of urinary EVs, Blood sample collection
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Mayo Clinic
Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
This phase II trial tests the safety of positron emission tomography (PET) guided stereotactic body radiation therapy (SBRT) and how well it works to treat non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma…
- Conditions
- Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT05830058
- Testing
- Biospecimen Collection, Computed Tomography, Positron Emission Tomography
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
Myeloma Multiple
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
This study is being done to answer the following question: Can the addition of daratumumab-hyaluronidase to the usual treatment of bortezomib and dexamethasone improve kidney function in patients who are newly diagnosed with…
- Trial name
- NCT07085728
- Testing
- Cyclophosphamide, Bortezomib (VELCADE), Dexamethasone
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Eastern Cooperative Oncology Group
Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC)
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
- Conditions
- Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- FIT-001 (NCT06026410)
- Testing
- Darlifarnib, Cabozantinib, Adagrasib
- Where
- 38 sites in United States, France and 3 more
- Volunteers
- 300 people
- Sponsor
- Kura Oncology, Inc.
Melanoma Stage IV, Head and Neck Squamous Cell Carcinoma
Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders
This is a single-arm, single-center, open-label, phase IIa study evaluating the safety, feasibility and efficacy of Faecal Microbiota Transplant (FMT) to cancer patients not responding to ICI therapy, using ICI-responders as…
- Conditions
- Melanoma Stage IV, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, MSI-High
- Trial name
- MITRIC (NCT05286294)
- Testing
- Fecal Microbiota Transplant (FMT)
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Oslo University Hospital